QCM
BEAM icon

Quantinno Capital Management’s Beam Therapeutics BEAM Stock Holding History

Quantinno Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$792K Buy
23,083
+7,007
+44% +$212K ﹤0.01% 2734
2026
Q1 		$383K Buy
16,076
+8,607
+115% +$239K ﹤0.01% 2895
2025
Q4 		$207K Buy
+7,469
New +$191K ﹤0.01% 3041

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Quantinno Capital Management's BEAM Position: Q2 2026 in Review

Quantinno Capital Management increased its Beam Therapeutics (BEAM) stake by 44% in Q2 2026, buying an estimated $212K and bringing the position to 23,083 shares worth $792K. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Quantinno Capital Management first reported a position in BEAM in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Quantinno Capital Management held 23,083 shares of Beam Therapeutics worth $792K as of Q2 2026.
  • Quantinno Capital Management bought 7,007 Beam Therapeutics shares in Q2 2026, an estimated $212K.
  • Beam Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2734 holding.
  • Quantinno Capital Management first reported a position in Beam Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.